Scienture Holdings Q3 revenue jumps on REZENOPY launch
Overview
US specialty pharma firm's Q3 2026 revenue grew yr/yr, driven by REZENOPY launch
Q3 gross profit rose 77.5% yr/yr to $1.02 mln, with gross margin at 81.3%
Outlook
Company expects to achieve breakeven operating income of $6 mln and profitability in 2027
Result Drivers
REZENOPY LAUNCH - Initial wholesale shipments of REZENOPY after its August 2026 launch generated about $925,000 in Q3 revenue and were the primary driver of sequential revenue growth
ARBLI SALES EXPANSION - Continued commercialization of Arbli, including increased formulary placements and growing institutional access, contributed to revenue growth; Arbli wholesale unit sales rose 74% sequentially
DISTRIBUTION AGREEMENTS - New direct customer distribution agreement for REZENOPY expanded access to about 2,000 opioid treatment clinics and addiction centers, broadening commercial reach beyond wholesale channels
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Gross Margin | 81.30% | ||
Q3 Gross Profit | $1.02 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Scienture Holdings Inc is $6.00, about 106.9% above its November 13 closing price of $2.90
Reuters Recommended Reads
Nov 16 - ALX Oncology Q3 net loss per share narrows
Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)